PeptideDeepDiveBuilt Because Clear Answers Were Hard to Find
I kept seeing the same problem: people were curious about peptides, but the information available was often overly technical, heavily promotional, or missing the context needed to judge a claim properly.
I wanted to create one place where readers could understand what the evidence says, where that evidence is limited, and how approved medicines, research compounds, and everyday supplements differ — without being pushed toward a decision.
What I Kept Running Into
Search for almost any peptide and the results split into two extremes. On one side: pages written to sell something, where every compound sounds like a breakthrough and the caveats are buried, if they appear at all. On the other: raw academic papers that are accurate but written for researchers, not for someone trying to make an actual decision about their health.
What was missing was the middle — content that took the research seriously enough to represent it accurately, but was written for a person, not a journal. That gap is the reason this site exists.
Why the Regulatory Distinction Matters So Much Here
One thing became clear early on: a huge amount of confusion in this space comes from treating “peptide” as if it were one category. It isn’t. Some peptides — like certain GLP-1 medications — have gone through full clinical trials and carry genuine FDA approval. Others, like BPC-157 and TB-500, are sold as research compounds with little to no human trial data behind them at all. Both get called “peptides.” Both get discussed in the same online spaces. That similarity in name hides a real difference in what’s actually known, and it’s a distinction I try to make explicit in everything published here — including our full recovery peptides ranked comparison.
How We Evaluate Evidence
Every guide on this site follows the same process: we start from the primary literature — clinical trials, systematic reviews, and regulatory filings — rather than secondary marketing copy. We state plainly when a compound’s evidence comes from animal studies rather than humans, when a trial was small or uncontrolled, and when a “well-studied” claim doesn’t hold up against what’s actually been published. Regulatory status (FDA, MHRA, EMA, HPRA, and equivalent bodies) is checked against primary sources, not vendor claims.
Evidence grading is never influenced by advertising or affiliate relationships.
Claims are checked against trial data and regulatory filings, not vendor copy.
Guides are revised as FDA, MHRA, and EMA status changes.
Clarity Before Complexity
Research should be explained in plain language without stripping away the details that actually matter. Simplifying a study shouldn’t mean distorting what it actually found.
Evidence Over Hype
Claims are separated from proven outcomes, and uncertainty is treated as useful information rather than something to hide. If the human data for a compound is thin, that’s a fact worth stating clearly, not softening.
Useful Without Pressure
The goal is to help readers make better-informed decisions, not manufacture urgency or sell a miracle. There’s no countdown timer here, no “limited time” framing — just information, presented as honestly as I can manage.
This site won’t tell you what to do. It will tell you what’s actually been studied, what hasn’t, and where a compound’s regulatory status stands right now — so that whatever decision you make, you’re making it with the real picture in front of you rather than a marketing version of it.
If that’s useful to you, the best place to start is the Research hub, our recovery peptides ranked comparison, or if you have a specific question, check the FAQ first, since there’s a good chance it’s already been answered there.
This page was last reviewed and updated in August 2026.